Cargando…

Structural studies of soluble guanylate cyclase

Detalles Bibliográficos
Autores principales:	Macdonald, Jane, Laffly, Emmanuelle, Garcin, Elsa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313356/ http://dx.doi.org/10.1186/1471-2210-9-S1-P43

Ejemplares similares

From biochemical and structural studies of soluble guanylate cyclase toward drug design
por: Laffly, Emmanuelle, et al.
Publicado: (2009)

Biochemical and structural characterization of C-terminal constructs of bovine soluble guanylate cyclase
por: Seeger, Franziska, et al.
Publicado: (2011)

Soluble guanylate cyclase crystal clear: 1(st) crystal structure of the wild-type human heterodimeric sGC catalytic domains and implications for activity
por: Seeger, Franziska, et al.
Publicado: (2013)

Thrombospondin-1 is a universal inhibitor of soluble guanylate cyclase activation
por: Miller, Thomas W, et al.
Publicado: (2009)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
por: Frey, Reiner, et al.
Publicado: (2013)

Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow
por: Rogers, Natasha M., et al.
Publicado: (2014)

Dynamics of NO interacting with soluble guanylate cyclase from 1 ps to 0.1 s and induced structural transitions
por: Yoo, Byung-Kuk, et al.
Publicado: (2011)

Blockade of CNG channels abrogates urethral relaxation induced by soluble guanylate cyclase activation
por: Triguero, Domingo, et al.
Publicado: (2009)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Effects of carbon monoxide-releasing molecules on cGMP levels and soluble guanylate cyclase activity
por: Marazioti, Antonia, et al.
Publicado: (2009)

Stimulation of soluble guanylate cyclase accelerates renal recovery following relief of unilateral ureteral obstruction
por: Wang-Rosenke, Yingrui, et al.
Publicado: (2009)

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
por: Frey, Reiner, et al.
Publicado: (2011)

Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteosomal degradation
por: Meurer, Sabine, et al.
Publicado: (2009)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension
por: Hoffmann, Linda S, et al.
Publicado: (2013)

Vasoprotection by heme oxygenase-1: interactions with soluble guanylate cyclase
por: Durante, William
Publicado: (2011)

Pharmacological activation of soluble guanylate cyclase activator protects the heart against isoproterenol-induced myocardial ischemia in rats
por: Korkmaz, Sevil, et al.
Publicado: (2009)

Heme oxygenase and soluble guanylate cyclase mediate the neutrophil migration failure to the lung in severe sepsis induced by pneumonia
por: Czaikoski, PG, et al.
Publicado: (2009)

Genetic mapping of a modifier locus affecting hypertension in soluble guanylate cyclase α(1) deficient mice
por: Buys, Emmanuel S, et al.
Publicado: (2011)

Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
por: Perez, Nisha, et al.
Publicado: (2013)

Discovery of neuroprotective soluble guanylate cyclase modulators (GCMs) aciting via NO/GC/cGMP/CREB pathway
por: Siklos, Marton I, et al.
Publicado: (2013)

The uremic retention solute p-cresyl sulfate alters NO signal transduction by alteration of the soluble guanylate cyclase redox state
por: Meijers, Björn KI, et al.
Publicado: (2009)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
por: Wittenborn, Elizabeth C., et al.
Publicado: (2021)

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
por: Scheerans, Christian, et al.
Publicado: (2011)

The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
por: Evgenov, Oleg V, et al.
Publicado: (2011)

Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
por: Boerrigter, Guido, et al.
Publicado: (2011)

Structure/function of the soluble guanylyl cyclase catalytic domain
por: Childers, Kenneth C., et al.
Publicado: (2018)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

Crystal Structures of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Allerston, Charles K., et al.
Publicado: (2013)

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure
por: Mitrovic, Veselin, et al.
Publicado: (2009)

Interfacial Residues Promote an Optimal Alignment of the Catalytic Center in Human Soluble Guanylate Cyclase: Heterodimerization Is Required but Not Sufficient for Activity
por: Seeger, Franziska, et al.
Publicado: (2014)

Inhaled and intravenous application of a stimulator of the soluble guanylate cyclase (BAY 41-8543) reduces pulmonary vascular resistance in a model of septic shock
por: Kronas, Nils, et al.
Publicado: (2011)

Nucleotidyl cyclase activity of recombinant soluble guanylyl cyclase
por: Rauch, Kerstin, et al.
Publicado: (2009)

Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development
por: Gileadi, Opher
Publicado: (2014)

Probing the Structural Dynamics of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Khalid, Rana Rehan, et al.
Publicado: (2020)

The discovery and characterization of novel soluble guanylate cyclase stimulators
por: Masferrer, Jaime L
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f8hspi1f96mcthh4er0niq386s